Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating: 5 out of 5

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.

Recs

0
Player Avatar ScreenerStizBear (< 20) Submitted: 6/26/2008 2:26:22 PM : Underperform Start Price: $14.63 IDRA Score: +98.81

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Featured Broker Partners


Advertisement